Bullish Analyst Sentiment on Nuvation Bio (NUVB) Amid Early Commercialization Progress

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 most active penny stocks to buy. Bullish Analyst Sentiment on Nuvation Bio (NUVB) Amid Early Commercialization Progress Photo by National Cancer Institute on Unsplash As of March 16, 2026, Wall Street remains optimistic about Nuvation Bio Inc. (NYSE:NUVB). With over 90% of analysts covering Nuvation Bio Inc. (NYSE:NUVB) maintaining bullish ratings, the consensus price target is $12.00, indicating a potential upside of 166.67%. As investors focus on IBTRO ...